Protection by a Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vaccine Expressing Shiga Toxin 2 B Subunit against Shiga Toxin-Producing Escherichia coli in Mice-Reference-Cited by-同舟云学术

Protection by a Recombinant Mycobacterium bovis Bacillus Calmette-Guérin Vaccine Expressing Shiga Toxin 2 B Subunit against Shiga Toxin-Producing Escherichia coli in Mice

Published:2012-12 Issue:12 Volume:19 Page:1932-1937
ISSN:1556-6811
Container-title:Clinical and Vaccine Immunology
language:en
Short-container-title:Clin Vaccine Immunol

Author:

Fujii Jun¹,Naito Mariko²,Yutsudo Takashi³,Matsumoto Sohkichi⁴,Heatherly Daniel P.⁵,Yamada Takeshi²,Kobayashi Hideyuki⁶,Yoshida Shin-ichi¹,Obrig Tom⁷

Affiliation:

1. Department of Bacteriology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

2. Microbiology and Oral Infection, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

3. Discovery Research Laboratory, Shionogi & Co., Ltd., Toyonaka City, Osaka, Japan

4. Department of Bacteriology, Osaka City University Graduate School of Medicine, Osaka, Japan

5. Department of Internal Medicine/Nephrology, University of Virginia, Charlottesville, Virginia, USA

6. Department of Chemistry, School of Medicine, University of Occupational and Environmental Health, Kitakyushu City, Japan

7. Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA

Abstract

ABSTRACT We have developed a novel vaccine against Shiga toxin (Stx)-producing Escherichia coli (STEC) infection using a recombinant Mycobacterium bovis BCG (rBCG) system. Two intraperitoneal vaccinations with rBCG expressing the Stx2 B subunit (Stx2B) resulted in an increase of protective serum IgG and mucosal IgA responses to Stx2B in BALB/c mice. When orally challenged with 10 3 CFU of STEC strain B2F1 (O91: H21), the immunized mice survived statistically significantly longer than the nonvaccinated mice. We suggest that intraperitoneal immunization with rBCG expressing Stx2B would be a potential vaccine strategy for STEC.

Publisher

American Society for Microbiology

Subject

Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy

Link

https://journals.asm.org/doi/pdf/10.1128/CVI.00473-12

Reference37 articles.

1. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR

2. Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine

3. Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease;Cohen A;Int. Immunol.,1990

4. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63;Connell ND;Proc. Natl. Acad. Sci. U. S. A.,1993

5. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of Trimethyl Chitosan Nanoparticles Containing Recombinant BLF1-stxB Protein of Burkholderia Pseudomallei and Evaluation of its Immunogenicity in Mice;Journal of Ilam University of Medical Sciences;2023-02-01

2. The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen;Microorganisms;2023-01-30

3. Diagnosis and Treatment for Shiga Toxin-Producing Escherichia coli Associated Hemolytic Uremic Syndrome;Toxins;2022-12-23

4. The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview;Frontiers in Microbiology;2021-10-21

5. Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli;Frontiers in Cellular and Infection Microbiology;2020-05-06